Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology
June 20th, 2007
Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced that the company's partner, Vical Incorporated, presented positive interim safety and tolerability data on 18 subjects from an ongoing Phase I clinical trial using Inovio's electroporation technology for intratumoral delivery into melanoma tumors of plasmid DNA (pDNA) encoding interleukin-2 (IL-2). The treatment demonstrated objective tumor responses in treated and untreated lesions. The data were presented at the annual meeting of the American Society of Clinical Oncology (Chicago, June 1-5) by Jon...
Source: Vaccine Weekly (2007-06-20)
|
